Durvalumab plus gefitinib displayed encouraging activity in TKI-naïve NSCLC patients with sensitizing EGFR mutations and was generally well tolerated [Ongoing Phase I open-label study]. Here, EGFR is linked to non-small cell lung carcinoma.